This article is part of the supplement: Advanced breast cancer therapy

Review

Triple-negative breast cancer

Reinaldo D Chacón^* and María V Costanzo

• * Corresponding author: Reinaldo D Chacón rchacon@alexanderfleming.org

Author Affiliations

Oncology Department, Instituto Alexander Fleming, Cramer 1180, zip code 1426 ANZ, Ciudad Autonoma de Buenos Aires, Argentina

For all author emails, please log on.

Breast Cancer Research 2010, 12(Suppl 2):S3 doi:10.1186/bcr2574

Published: 22 October 2010

Abstract

Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-called basaloid tumors are not always synonymous with TN tumors; they differ in the fact that they express different molecular markers, have a higher histologic grade, and have a worse prognosis. Clinically they occur in younger women as interval cancer, and the risk of recurrence is higher within the first 3 years. Distant recurrences in the brain and visceral metastases are more common than in hormone receptor-positive tumors. Therapeutically, despite being highly chemosensitive, their progression-free time is generally short. In terms of chemotherapeutic treatment, anthracyclines and taxanes are useful drugs, and high response rates have been described for the combination of ixabepilone-capecitabine and platinums. The combination with antiangiogenic drugs has also proven useful. A group of new drugs, poly-(ADP-ribose)-polymerase inhibitors, showed favorable results in TN tumors with BRCA mutation. There are currently several ongoing studies with new drugs including epidermal growth factor receptor inhibitors, c-kit inhibitors, Raf/Mek/Map kinase inhibitors and mTOR inhibitors.